Objectives: Limited treatment options available for Mycobacterium abscessus infections include the parenteral b-lactam antibiotics cefoxitin and imipenem, which show moderate in vitro activity. Other b-lactam antibiotics (except meropenem) have no considerable in vitro activity, due to their rapid hydrolysis by a broad-spectrum b-lactamase (Bla_Mab). We here addressed the impact of b-lactamase production and b-lactam in vitro stability on M. abscessus MIC results and determined the epidemiological cut-off (ECOFF) values of cefoxitin, imipenem and meropenem.
Introduction
Mycobacterium abscessus is a dreadful and arduous to treat mycobacterial pathogen with a high level of innate resistance to most commercially available antibiotics, including the antituberculous agents. [1] [2] [3] [4] [5] Clinically relevant cases are predominantly associated with pulmonary infections in patients with cystic fibrosis or bronchiectasis and disseminated disease in immunocompromised individuals.
2-4 M. abscessus is also highly resistant to disinfectants and therefore it ordinarily causes skin and soft tissue infections following plastic surgery, tattooing or body piercing. 3, [5] [6] [7] [8] Several healthcare-associated outbreaks of M. abscessus infections, that have been reported worldwide, highlight the increasing medical importance of this MDR pathogen and the urgent need for reliable medication strategies. 3, 4, 9 As M. abscessus clinical isolates are uniformly resistant to standard chemotherapeutic agents, so far, no reliable antibiotic regimen for M. abscessus pulmonary infections has been established. Antibiotic administration is empirical and heavily relies on in vitro antibiotic susceptibility testing (AST) by broth microdilution and definitive subspecies identification. 3, 10 The clinical importance of M. abscessus subspecies identification (M. abscessus subsp. abscessus, M. abscessus subsp. bolletii and M. abscessus subsp. massiliense) is attributed to the fact that M. abscessus subsp. abscessus and M. abscessus subsp. bolletii have a functional inducible erythromycin ribosome methyltransferase gene [erm (41) ], which confers macrolide resistance, whereas M. abscessus subsp. massiliense has a nonfunctional erm (41) , leading to macrolide susceptibility, and thus M. abscessus subsp. massiliense infections have more favourable prognosis and treatment outcomes. [10] [11] [12] [13] [14] [15] [16] [17] [18] The American Thoracic Society recommends for the treatment of M. abscessus lung infections a combination therapy of an oral macrolide (clarithromycin or azithromycin) for clinical isolates susceptible to macrolides and the intravenous aminoglycoside drug amikacin, administered together with a parenteral b-lactam antibiotic, cefoxitin or imipenem. 3, [19] [20] [21] However, with the exception of the macrolide class, very limited data are present in the literature concerning the correlation between AST and the clinical efficacy of these recommended antimycobacterial drugs. 22 The clinical relevance of AST remains a controversy, particularly on account of technical problems associated with AST methods, reproducibility of AST results, significant discrepancies between in vitro susceptibility and in vivo activity of a given drug and solubility and stability issues of the drugs used. 23 Ideally, clinicians could take advantage of AST for M. abscessus, when the in vitro susceptibility to a drug is consistent with a clinically achievable drug exposure in vivo, resulting in favourable treatment outcomes. Accordingly, clinical susceptibility breakpoints must represent MIC distributions and zone diameter distributions for WT and resistant strains, resistance mechanisms, dosing regimens, drug pharmacokinetics, pharmacodynamics and epidemiological cutoff (ECOFF) values and must allow prediction of treatment outcomes. [22] [23] [24] [25] CLSI is the only organization worldwide that has published AST guidelines for rapid growing mycobacteria 24 recommending susceptibility testing of amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline or minocycline, imipenem, linezolid, moxifloxacin, trimethoprim/sulfamethoxazole and tobramycin. 25 The breakpoint concentrations for these antibiotics have nonetheless been set on the basis of in vitro driven studies and their efficacy (except the new drugs linezolid and tigecycline) has been clinically evaluated by Wallace et al. 26 principally in patients with extrapulmonary disease. To date, EUCAST has not officially announced guiding principles for nontuberculous mycobacteria susceptibility testing.
Frequently used therapeutics for M. abscessus infections are the parenteral b-lactam antibiotics cefoxitin and imipenem, 24 which have moderate in vitro activity, with MIC values reported by Dubée et al. 27 for M. abscessus subsp. abscessus CIP 104536 of 32 and 8 mg/L, respectively. Meropenem, an ultra-broadspectrum carbapenem closely related to imipenem, 28 displayed a lower MIC value (16 mg/L) than cefoxitin for M. abscessus subsp. abscessus CIP 104536. 27 Most of the other b-lactam antibiotics have no considerable in vitro activity due to their rapid hydrolysis by a broad-spectrum class A b-lactamase, encoded by MAB_2875, namely Bla_Mab, which was reported as the major determinant of b-lactam resistance in M. abscessus.
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Determination of the kinetic parameters of this enzyme revealed that it can slowly hydrolyse imipenem and meropenem, while cefoxitin hydrolysis by Bla_Mab is immensely slow, as the methoxy group at cefoxitin's b-lactam ring was predicted to block the activity of class A b-lactamases. 27, 29, 30 As imipenem, meropenem and cefoxitin are known to have limited in vitro stability, 31 we assessed by LC high-resolution MS (LC-HRMS) the in vitro stability of these b-lactams and, by exploiting a bla Mab deletion mutant that we generated, we addressed the biological effect of b-lactam stability and b-lactamase production on MIC testing results after different periods of incubation. The direct impact of b-lactam stability on AST testing was further addressed by MIC determination of fresh and pre-incubated b-lactam antibiotics for the ampicillin- 
Definitive subspecies identification of clinical isolates
Subspecies identification of M. abscessus isolates (M. abscessus subsp. abscessus, M. abscessus subsp. bolletii and M. abscessus subsp. massiliense) was based on the 16S rRNA, rpoB and erm(41) gene sequences. [12] [13] [14] 32, 33 Subspecies attribution for M. abscessus complex isolates was performed according to Tortoli et al. 12 The obtained sequences were analysed with the use of Lasergene SeqMan software (DNASTAR, USA), the SmartGene IDNS mycobacteria and rpoB databases (SmartGene, Switzerland), and the BLAST algorithm (http://blast.ncbi.nlm.nih.gov).
Antibiotics
Imipenem, meropenem, cefoxitin, ceftriaxone, ceftazidime, penicillin G, ampicillin, amoxicillin, amikacin, apramycin and isoniazid were bought from Sigma-Aldrich, Switzerland. All compounds were dissolved in H 2 O, according to the manufacturer's recommendations, filter sterilized, aliquoted into stock solutions of 3-50 g/L and finally stored at #20 C.
Deletion of MAB_2875 in M. abscessus 
0 , respectively) and cloned into the pSE-katG-aac(3)IV vector with corresponding enzymes, resulting in the bla Mab deletion vector pSE-katG-aac(3)IV-DMAB_2875. M. abscessus bla Mab deletion mutant was generated using a double selection strategy described previously in detail by Rominski et al. 34, 35 In brief, pSE-katG-aac(3)IV-DMAB_2875 was transformed into electrocompetent M. abscessus ATCC 19977. Competent cells (100 lL) were mixed with 1-2 lg of plasmid DNA (supercoiled) and electroporated in a Bio-Rad Gene pulser II using 4 mm gap electroporation cuvettes and the settings: 2.5 kV, 1000 X and 25 lF. 36 Cells were resuspended after electroporation in 0.9 mL of 7H9-OADC-Tween 80 liquid medium and incubated for 5 h at 37 C. Proper dilutions were eventually Impact of Bla_Mab and b-lactam instability on M. abscessus AST JAC plated on selective agar and, after 5 days of incubation, single colonies were picked and restreaked on LB agar plates with appropriate antibiotics. Transformants were selected on LB agar plates containing apramycin and identified by aac(3)IV colony PCR (primers: 5 0 -CACCTTCTTCACGAGG CAGACCTC-3 0 and 5 0 -GGTCTGACGCTCATGGAACTAGTAGG-3 0 ). Isolation of genomic DNA was performed by phenol-chloroform-isoamyl alcohol extraction as described previously 37 and single crossover transformants were confirmed by Southern blot analysis with a 0.45 kbp SacI 3 0 bla Mab DNA probe and subjected to counterselection on LB agar plates containing isoniazid. Single colonies were screened for deletion of MAB_2875 by PCR (primers: 5 0 -GTACACCGTCTTCGGGACG-3 0 and 5 0 -GAAAGTGCGAGTACGCGTCTG-3 0 ) and their genotype was finally verified by Southern blot analysis using the same 0.45 kbp SacI 3 0 bla Mab DNA probe. In this way, a 0.63 kbp region of the MAB_2875 was deleted from the genome of M. abscessus ATCC 19977.
Nitrocefin test
For the detection of b-lactamase production in the M. abscessus ATCC 19977 type strain and the Dbla Mab mutant strain we performed a chromogenic nitrocefin test (Becton Dickinson, USA). Tubes containing (i) pure nitrocefin solution, (ii) nitrocefin solution inoculated with five colonies of the M. abscessus ATCC 19977 type strain and (iii) nitrocefin solution inoculated with five colonies of the M. abscessus Dbla Mab mutant were incubated for 1 h at room temperature before a photo was taken.
MIC assays
MIC assays were performed with the microdilution method and according to CLSI guidelines, 25 but with incubation of the 96-well microtitre plates at 37 C, as described previously. 34, 35 Directly after the preparation of the antibiotic stock solutions, working solutions were prepared by diluting the corresponding stock solutions in CAMHB (pH 7.4) (Becton Dickinson, Switzerland) to a concentration of 512 mg/L (final antibiotic concentration used for AST; 256 mg/L) and were subsequently stored at #80 C. Shortly before the conduct of an MIC experiment (day 0), working solutions were thawed for the first time and were directly used. Alternatively, working solutions were thawed and pre-incubated for 1-7 days at 37 C and their inhibitory effect was compared with freshly thawed antibiotics. Two-fold serial dilutions of the freshly thawed (and pre-incubated: for the pre-incubation MIC experiments) working solutions were prepared using CAMHB in sterile 96-well microtitre plates (Greiner Bio-One, Switzerland). Each 96-well microtitre plate included a positive growth control lacking antibiotic and a sterile negative control containing only CAMHB. To achieve a final inoculum titre of 1-5%10 5 cfu/mL, while final volume per well was 100 lL, bacterial suspensions of strains with smooth or rough phenotypes were adjusted to a McFarland standard of 0.5 and 3.0, respectively, and subsequently diluted in CAMHB. The proper titre of the inocula was confirmed by obtaining cfu counts on LB agar plates. MIC values were assessed by visual inspection after incubation at 37 C for 16 h for E. coli strains and 3, 5, 7 and 12 days for M. abscessus. MIC assays for E. coli, M. abscessus ATCC 19977 and the M. abscessus bla Mab deletion mutant were conducted in triplicate. MIC assays for M. abscessus complex clinical isolates were performed once.
LC-HRMS assays
In vitro antimicrobial stability of cefoxitin, imipenem and meropenem was evaluated using CAMHB and the maximum final antibiotic concentration used for AST (256 mg/L). A different test tube was prepared for each antibiotic and for every reading timepoint, i.e. 3, 5, 7 and 12 days. A day 0 control was used to define the 100% relative antibiotic concentration. The antibiotic-containing test tubes were incubated under the same temperature conditions as the microtitre plates used for AST (37 C) . Cefoxitin, imipenem and meropenem were quantified by LC-HRMS on a Q Exactive hybrid instrument (Thermo Fisher, Switzerland). Samples were precipitated using a precipitation solution consisting of methanol/acetonitrile (80/20, v/v), containing the corresponding stable-isotope labelled internal standards. After centrifugation at 11700 g for 10 min at 4 C, 10 lL of the clear supernatant was injected into the turbulent flow online extraction system. As extraction column a Cyclone column (50%0.5 mm) was used and for analytical chromatography a Hypersil Gold C8 column (100%3 mm) was used. Mobile phases consisted of 10 mM ammonium acetate in water-! 0.1% formic acid and 10 mM ammonium acetate in methanol/acetonitrile (50/50, v/v) ! 0.1% formic acid. Samples were analysed in positive heated electrospray ionization mode and detection was done in full-scan mode with a resolution of 70000 full width at half maximum (calculated for m/z 200).
ECOFF determination
MIC data for 62 M. abscessus complex clinical isolates were collected and the resistance population analysis charts were calculated using the integrated histographical analysis tool of Microsoft Excel. Median MIC 50 values of cefoxitin, imipenem and meropenem for the M. abscessus complex clinical strains were calculated using SPSS software. All ECOFF values were determined by the eyeball method.
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Results and discussion
Generation of the M. abscessus MAB_2875 deletion mutant
Similarly to our previously published techniques, 34, 35 we intended to generate an M. abscessus DMAB_2875 mutant, which would enable us to address directly the role of the b-lactamase production of M. abscessus on MIC testing results of b-lactam antibiotics. The bla Mab deletion mutant was constructed by transformation of M. abscessus ATCC 19977 with plasmid pSE-katG-aac(3)IV-DMAB_2875 applying an apramycin-positive selection 40 and a katGdependent isoniazid counterselection strategy (Figure 1a) . 34, 35 Deletion of MAB_2875 was confirmed by Southern blot analysis (Figure 1b) . While this study was ongoing, a DMAB_2875 mutant was also generated by Dubée et al., 27 but with different cloning, genetic manipulation and selection strategies.
M. abscessus bla Mab deletion mutant is deficient in b-lactamase production
To assess the b-lactamase production of the M. abscessus Dbla Mab mutant, we performed a chromogenic nitrocefin test. The cephalosporin nitrocefin changes colour from yellow to red in the presence of b-lactamases that hydrolyse the amide bond in its b-lactam ring. 41 As Figure 2 shows, the tube containing yellow pure nitrocefin solution (Figure 2a (Table 1 ) agree with earlier reported data, 27 corroborating previous molecular modelling and structural analyses, 42 which delineated that substitutions of the b-lactam ring by a methoxy group in cefoxitin inhibits the activity of class A b-lactamases. 30 As expected, amikacin MICs were independent of the bla genotype.
To date, none of the recent studies on b-lactam susceptibility testing of M. abscessus CIP 104536 and the M. abscessus Dbla Mab mutant has reported MIC data obtained after 3 days of incubation. 27, 29, 30, 43, 44 Indeed, CLSI guidelines 25 for imipenem MIC testing for rapid growing mycobacteria recommends a maximum incubation period of 3 days and state that 'the reported breakpoints for imipenem are considered tentative'. Our observation that imipenem, meropenem and cefoxitin MIC values rise substantially with the incubation time for both the M. abscessus ATCC 19977 strain and the M. abscessus Dbla Mab mutant (Table 1) , in correlation with the fact that certain antibiotics undergo partial degradation 
Effect of b-lactam stability on E. coli MIC testing
To determine experimentally whether the results of the M. abscessus MIC testing of b-lactams after 3, 5 and 7 days of incubation clearly reflect b-lactamase production or are affected by instability of the antibiotics tested, we performed an MIC experiment using the E. coli XL1-Blue model strain, which produces no b-lactamases, and fresh and pre-incubated (at 37 C, for 1-7 days) b-lactam antibiotics. In that way, all MIC results could be obtained after 16 h of incubation of the microtitre plates and putative MIC differences between the fresh and the pre-incubated antibiotics could be directly correlated to instability of the tested antibiotics. Our results show that pre-incubation at 37 C affects MIC results of imipenem, meropenem and to a lesser extent cefoxitin and ceftazidime (Figure 3a and b) , whereas the MIC results of ceftriaxone, penicillin G, ampicillin, amoxicillin and as expected the control stable aminoglycoside antibiotic amikacin are not influenced by preincubation (Figure 3b, c and d) . By assuming that drug degradation follows an exponential decay process and using the data displayed in Figure 3 , we calculated the half-life values of imipenem as 0.75 days, of meropenem as 1.5 days and of cefoxitin as 3 days. We therefore conclude that the increased MIC values of the preincubated antibiotics, already before day 3, reflect instability of the antibiotics. Reading of M. abscessus MICs at day 3 and later gives a de facto misleading impression for the true extent of activity of imipenem, meropenem and cefoxitin.
In vitro antimicrobial stability of cefoxitin, imipenem and meropenem by LC-HRMS Based on our results suggesting that incubation of cefoxitin, imipenem and meropenem at 37 C gives rise to misleading MIC Rominski et al.
results, we intended to address the in vitro stability of these b-lactams, by quantifying them using LC-HRMS. Tubes containing CAMHB and the maximum antibiotic concentration used for AST (256 mg/L) were incubated at 37 C. The 100% relative antibiotic concentration of each antibiotic was defined by a day 0 control tube. On days 3, 5, 7 and 12 the concentrations of cefoxitin, imipenem and meropenem were quantified. Data obtained by the LC-HRMS method, clearly show degradation of cefoxitin, imipenem and meropenem. Particularly, the relative concentration on day 3 for imipenem dramatically dropped to 3.3%, whereas for cefoxitin and meropenem it dropped to 36.6% and 35.6%, respectively (Figure 4e, j and o) . By using the results of this assay, the calculated half-life of imipenem was 0.6 days, that of meropenem was 2 days and that of cefoxitin was 2.1 days. These findings agree with those deducted from the E. coli MIC testing and confirm that the MIC values of cefoxitin, imipenem and meropenem for M. abscessus on day 3 and later are misleading, as concentration of the active compound is lowered. Particularly for imipenem, MIC 50 on day 3 was 16 mg/L (Figure 4j ). However, growth inhibition of half of the clinical isolates was in reality achieved by considerably lower drug amounts, as the true active relative concentration of imipenem shrank to 3.3% by day 3 due to the short half-life of this antibiotic. Consequently, due to instability of imipenem, meropenem and cefoxitin, M. abscessus MIC determination after 3 days of incubation does not reflect the potency of these three compounds, particularly as clinical administration 3 of these drugs is daily and in multiple doses. These data, on the one hand, question the utility of susceptibility testing of imipenem, meropenem and cefoxitin, but, on the other hand, support administration of these parenteral b-lactam antibiotics as part of combinational regimens for the treatment of M. abscessus infections.
ECOFF values of cefoxitin, imipenem and meropenem for M. abscessus complex
According to EUCAST, for the determination of clinical susceptibility breakpoint values and improvement of the MIC interpretation for clinical isolates, ECOFFs need to be defined to separate the WT population from any non-WT strains with acquired drug resistance mechanisms to the chemotherapeutic agents in question. 46 We therefore endeavoured to estimate ECOFF values of cefoxitin, imipenem and meropenem by visual inspection of the MIC histographic distribution analysis (eyeball method) 36, 37 for 62 M. abscessus complex clinical strains isolated from respiratory samples, after 3, 5, 7 and 12 days of incubation at 37 C (Figure 4) . The results show that MIC distributions for our collection of M. abscessus complex isolates of cefoxitin, imipenem and meropenem are close to the breakpoints established by CLSI and that the eyeball-estimated ECOFF values did not show a separation of the M. abscessus complex isolates into two distinct subgroups, WT and resistotype. ECOFFs were set at the highest MIC value observed among the isolates tested and all of these isolates are therefore classified in the WT subgroup. According to this classification, a putative clinical isolate with an additional b-lactam resistance mechanism would have a very high MIC value (higher than the corresponding ECOFF) that would be neither detected by standard AST laboratory procedures nor relevant for clinical interpretation. Interestingly, the presence or absence of a functional or non-functional b-lactamase in M. abscessus could not be predicted by the MIC distribution for the clinical isolates, as the MIC values determined for M. abscessus Dbla Mab (Table 1) 
Conclusions
Taken together, our study confirmed Bla_Mab as the major determinant of innate b-lactam resistance in M. abscessus and addressed experimentally the biological effect of b-lactamase production and b-lactam stability on M. abscessus MIC testing results after different incubation periods. Our results show that MIC, MIC 50 and ECOFF values of cefoxitin, imipenem and meropenem are immensely influenced by incubation time. LC-HRMS data and MIC determination of pre-incubated drugs for the fast growing model organism (E. coli) proved significant degradation of cefoxitin, imipenem and meropenem during standard AST procedures, explaining the problematic correlation between in vitro susceptibility of these three b-lactams and their in vivo activity. Our findings critically question the clinical utility of cefoxitin, imipenem and meropenem susceptibility testing, but further support administration of these chemotherapeutic agents for the treatment of M. abscessus infections. Rominski et al.
